A Rizos1, A Sauerbier1,2, A Antonini3, D Weintraub4, P Martinez-Martin5, B Kessel6, T Henriksen7, C Falup-Pecurariu8, M Silverdale9, G Durner1, K Røkenes Karlsen1, M Grilo1, P Odin10,11, K Ray Chaudhuri1,2,12. 1. King's College Hospital, London, UK. 2. King's College London, London, UK. 3. Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice and University of Padua, Padua, Italy. 4. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 5. National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain. 6. King's College Hospital, Princess Royal University Hospital site, Orpington, UK. 7. University Hospital of Bispebjerg, Copenhagen, Denmark. 8. County Emergency Clinic Hospital, Faculty of Medicine, Transilvania University Brasov, Brasov, Romania. 9. Greater Manchester Neuroscience Centre, Manchester, UK. 10. University of Lund, Lund, Sweden. 11. University Hospital Reinkenheide, Bremerhaven, Germany. 12. University Hospital Lewisham, London, UK.
Abstract
BACKGROUND AND PURPOSE: Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PD patients across several European centres treated with short- or long-acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care. METHODS: A survey based on medical records and clinical interviews of patients initiating or initiated on DA treatment (both short- and long-acting, and transdermal) across a broad range of disease stages and age groups was performed. RESULTS: Four hundred and twenty-five cases were included [mean age 68.3 years (range 37-90), mean duration of disease 7.5 years (range 0-37)]. ICD frequencies (as assessed by clinical interview) were significantly lower with RTG (4.9%; P < 0.05) compared with any other assessed DAs except for prolonged release PPX (PPX-PR). The rate of ICDs for PPX-PR (6.6%) was significantly lower than for immediate release PPX (PPX-IR) (19.0%; P < 0.05). Discontinuation rates of DA therapy due to ICDs were low. CONCLUSION: Our data suggest a relatively low rate of ICDs with long-acting or transdermal DAs, however these preliminary observational data need to be confirmed with prospective studies controlling for possible confounding factors.
BACKGROUND AND PURPOSE: Impulse control disorders (ICDs) in Parkinson's disease (PD) are associated primarily with dopamine agonist (DA) use. Comparative surveys of clinical occurrence of impulse control behaviours on longer acting/transdermal DA therapy across age ranges are lacking. The aim of this study was to assess the occurrence of ICDs in PDpatients across several European centres treated with short- or long-acting [ropinirole (ROP); pramipexole (PPX)] and transdermal [rotigotine skin patch (RTG)] DAs, based on clinical survey as part of routine clinical care. METHODS: A survey based on medical records and clinical interviews of patients initiating or initiated on DA treatment (both short- and long-acting, and transdermal) across a broad range of disease stages and age groups was performed. RESULTS: Four hundred and twenty-five cases were included [mean age 68.3 years (range 37-90), mean duration of disease 7.5 years (range 0-37)]. ICD frequencies (as assessed by clinical interview) were significantly lower with RTG (4.9%; P < 0.05) compared with any other assessed DAs except for prolonged release PPX (PPX-PR). The rate of ICDs for PPX-PR (6.6%) was significantly lower than for immediate release PPX (PPX-IR) (19.0%; P < 0.05). Discontinuation rates of DA therapy due to ICDs were low. CONCLUSION: Our data suggest a relatively low rate of ICDs with long-acting or transdermal DAs, however these preliminary observational data need to be confirmed with prospective studies controlling for possible confounding factors.
Authors: Tamara Pringsheim; Gregory S Day; Don B Smith; Alex Rae-Grant; Nicole Licking; Melissa J Armstrong; Rob M A de Bie; Emmanuel Roze; Janis M Miyasaki; Robert A Hauser; Alberto J Espay; Justin P Martello; Julie A Gurwell; Lori Billinghurst; Kelly Sullivan; Michael S Fitts; Nicholas Cothros; Deborah A Hall; Miriam Rafferty; Lynn Hagerbrant; Tara Hastings; Mary Dolan O'Brien; Heather Silsbee; Gary Gronseth; Anthony E Lang Journal: Neurology Date: 2021-11-16 Impact factor: 9.910
Authors: Paloma Parra-Díaz; Juan Luis Chico-García; Álvaro Beltrán-Corbellini; Fernando Rodríguez-Jorge; Clara Lastras Fernández-Escandón; Araceli Alonso-Cánovas; Juan Carlos Martínez-Castrillo Journal: Mov Disord Clin Pract Date: 2020-12-21
Authors: A Antonini; K R Chaudhuri; B Boroojerdi; M Asgharnejad; L Bauer; F Grieger; D Weintraub Journal: Eur J Neurol Date: 2016-07-18 Impact factor: 6.089